Search Results - "Chiu, J.W.Y."

859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial by Michel, L., Jimeno, A., Sukari, A., Beck, T., Chiu, J.W.Y., Ahern, E.S., Hilton, J., A. Hollebecque, Zanetta, S., Patel, J., Mekan, S., Wu, T., Dumbrava, E.E.

Get full text

48P Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE by Yap, Y-S., Kim, S-B., Chiu, J.W.Y., Lim, E., Broom, R., Liu, Z., Sagara, Y., Chao, T-Y., Sherwood, S., McNaughton, R.E., Wei, R.J., Toi, M.

Get full text

1589TiP - KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) by Gutierrez, M., Lam, W.-S., Hellmann, M.D., Gubens, M.A., Aggarwal, C., Tan, D.S.W., Felip, E., Chiu, J.W.Y., Lee, J.S., Yang, J C-H, Garon, E.B., Basso, A., Ma, H., Fong, L., Snyder, A., Yuan, J., Herbst, R.S.

“…KEYNOTE-495 is a randomized, open-label, phase II trial (NCT03516981) evaluating the clinical activity and safety of pembrolizumab (pembro)-based combination…”
Get full text

KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) by Gutierrez, M., Lam, W.-S., Hellmann, M.D., Gubens, M.A., Aggarwal, C., Tan, D.S.W., Felip, E., Chiu, J.W.Y., Lee, J.S., Yang, J C-H, Garon, E.B., Basso, A., Ma, H., Fong, L., Snyder, A., Yuan, J., Herbst, R.S.

Get full text

P-270 Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong by Lam, K.O., Lee, K.C., Lee, V.H.F., Sze, H.C.K., Chiu, J.W.Y., Leung, R., Yau, T.

Get full text

71P Evolution of neoadjuvant chemotherapy (NAC) in locally advanced HER2-positive breast cancer over 10 years in Hong Kong by Chiu, J.W.Y., Leung, R., Tang, V., Cheuk, I., Lo, J., Wong, H., Kwok, G., Suen, D., Yau, T., Kwong, A.

Get full text

Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy by Lee, S.C., Chen, S-C, Dai, M-S, Lee, G.E., Liu, C-L, Chan, A., Chang, H-K, Tseng, L-M, Chay, W.Y., Chow, L.W.C., Peneyra, J.L., Rau, K-M, Wang, H-C, Guancia, A.A., Head, M., Chiu, J.W.Y., Robinson, B., Lindmark, B., McIntyre, N., Hsieh, C-Y

Get full text